Double maintains 3 strategies that include IONS - Ionis Pharmaceuticals, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
LGOV | -<0.01% | $708.16M | 0.67% |
SUB | 0.01% | $9.91B | 0.07% |
SGOL | 0.08% | $5.22B | 0.17% |
IAU | 0.11% | $47.14B | 0.25% |
BAR | 0.12% | $1.12B | 0.1749% |
IBTP | 0.18% | $142.44M | 0.07% |
OUNZ | 0.23% | $1.74B | 0.25% |
GLD | 0.25% | $101.85B | 0.4% |
BSMR | 0.29% | $255.58M | 0.18% |
USDU | 0.39% | $162.92M | 0.5% |
CGCB | 0.44% | $2.47B | 0.27% |
ITM | 0.46% | $1.87B | 0.18% |
AAAU | 0.46% | $1.56B | 0.18% |
GVI | 0.49% | $3.40B | 0.2% |
MMIT | -0.55% | $1.02B | 0.3% |
FLGV | -0.69% | $1.01B | 0.09% |
GLDM | -0.70% | $15.83B | 0.1% |
FXE | -0.72% | $568.58M | 0.4% |
GOVT | 0.72% | $27.51B | 0.05% |
FMB | -0.80% | $1.90B | 0.65% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -35.29% | $165.69M | 0.85% |
TAIL | -34.91% | $99.76M | 0.59% |
BTAL | -30.66% | $296.79M | 1.43% |
TPMN | -21.03% | $30.81M | 0.65% |
IVOL | -19.93% | $349.27M | 1.02% |
SHYM | -19.20% | $350.04M | 0.35% |
FXY | -17.07% | $815.67M | 0.4% |
FTSD | -16.09% | $231.79M | 0.25% |
SPTS | -15.96% | $5.78B | 0.03% |
ULST | -15.69% | $662.59M | 0.2% |
BIL | -12.77% | $42.87B | 0.1356% |
CTA | -11.37% | $1.06B | 0.76% |
UTWO | -11.33% | $379.36M | 0.15% |
STPZ | -11.03% | $450.22M | 0.2% |
SCHO | -10.64% | $11.46B | 0.03% |
TBLL | -10.03% | $2.13B | 0.08% |
VGSH | -9.73% | $22.80B | 0.03% |
IBTG | -9.69% | $1.92B | 0.07% |
TFLO | -9.67% | $6.83B | 0.15% |
IBDQ | -9.65% | $2.99B | 0.1% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 65.45% | $4.95B | 0.35% |
IBB | 63.35% | $5.36B | 0.45% |
PBE | 60.84% | $223.24M | 0.58% |
FBT | 60.68% | $1.01B | 0.54% |
GNOM | 59.71% | $44.43M | 0.5% |
BBH | 59.39% | $329.82M | 0.35% |
PINK | 55.42% | $133.06M | 0.5% |
ARKG | 54.40% | $1.05B | 0.75% |
XPH | 52.01% | $149.79M | 0.35% |
VHT | 50.85% | $15.31B | 0.09% |
FHLC | 50.77% | $2.43B | 0.084% |
FXH | 50.03% | $898.02M | 0.62% |
IYH | 48.90% | $2.71B | 0.39% |
PTH | 48.05% | $101.07M | 0.6% |
IXJ | 47.99% | $3.74B | 0.41% |
QQQJ | 47.82% | $617.03M | 0.15% |
RSPH | 47.12% | $731.31M | 0.4% |
XLV | 46.38% | $34.14B | 0.09% |
MOAT | 46.15% | $12.59B | 0.47% |
IWO | 45.49% | $11.48B | 0.24% |
Current Value
$39.951 Year Return
Current Value
$39.951 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LITB | -15.42% | $21.70M | -78.27% | 0.00% |
CBOE | -11.43% | $23.98B | +34.66% | 1.10% |
VSA | -10.33% | $8.67M | -15.70% | 0.00% |
VSTA | -8.57% | $342.46M | +40.00% | 0.00% |
MSIF | -7.81% | $769.00M | +36.08% | 6.63% |
VHC | -7.75% | $45.90M | +59.26% | 0.00% |
LFVN | -6.88% | $159.74M | +97.66% | 1.30% |
CME | -6.64% | $99.01B | +39.76% | 3.87% |
EXC | -6.25% | $43.32B | +23.98% | 3.65% |
VZ | -6.16% | $178.39B | +2.59% | 6.38% |
AIFU | -5.41% | $6.13B | +82.50% | 0.00% |
AWK | -5.36% | $26.90B | +6.78% | 2.27% |
ED | -4.83% | $35.36B | +9.76% | 3.39% |
K | -4.80% | $27.41B | +36.96% | 2.88% |
TRUG | -4.22% | $6.34M | -88.80% | 0.00% |
KR | -3.73% | $47.56B | +43.04% | 1.79% |
ZCMD | -3.67% | $28.79M | -13.64% | 0.00% |
MKTX | -3.53% | $8.23B | +9.48% | 1.37% |
T | -3.50% | $202.05B | +46.94% | 3.95% |
AGRO | -2.97% | $905.94M | -6.89% | 3.85% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ALNY | 58.16% | $42.09B | +32.85% | 0.00% |
IDYA | 50.95% | $1.87B | -39.13% | 0.00% |
IQV | 49.54% | $27.24B | -25.53% | 0.00% |
IMVT | 48.68% | $2.75B | -39.02% | 0.00% |
XENE | 48.61% | $2.49B | -16.90% | 0.00% |
ROIV | 48.47% | $7.74B | +7.76% | 0.00% |
ARWR | 47.74% | $2.22B | -38.13% | 0.00% |
BEAM | 47.21% | $1.69B | -28.30% | 0.00% |
CRNX | 47.04% | $2.81B | -33.11% | 0.00% |
RARE | 46.42% | $3.45B | -11.14% | 0.00% |
SHC | 46.28% | $3.21B | -4.63% | 0.00% |
DHR | 45.93% | $142.28B | -20.43% | 0.73% |
BRKR | 45.76% | $6.33B | -34.49% | 0.48% |
DNLI | 45.53% | $2.05B | -39.28% | 0.00% |
SYRE | 45.41% | $918.58M | -35.26% | 0.00% |
A | 45.30% | $33.85B | -8.07% | 0.81% |
RGEN | 44.64% | $6.94B | -1.98% | 0.00% |
TECH | 44.44% | $8.13B | -27.65% | 0.62% |
TMO | 44.33% | $154.12B | -26.17% | 0.40% |
CGON | 44.27% | $1.98B | -17.80% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PRA | -0.15% | $1.17B | +86.82% | 0.00% |
CREG | 0.26% | $5.81M | -77.49% | 0.00% |
AQB | 0.27% | $2.84M | -54.35% | 0.00% |
AWR | -0.29% | $2.94B | +5.29% | 2.44% |
CI | 0.29% | $87.17B | -1.29% | 1.78% |
NEUE | 0.42% | $61.96M | +27.57% | 0.00% |
CCEC | 0.42% | $1.02B | +3.91% | 2.61% |
FUBO | -0.48% | $1.21B | +184.68% | 0.00% |
PRPO | -0.57% | $16.43M | +109.40% | 0.00% |
PPC | -0.64% | $10.57B | +30.66% | 0.00% |
KNOP | 0.69% | $219.16M | -27.14% | 1.64% |
TDUP | -0.76% | $880.94M | +338.24% | 0.00% |
CVGW | -0.84% | $479.64M | +18.46% | 2.63% |
UUU | -0.88% | $6.64M | +78.38% | 0.00% |
PARAA | 0.90% | $15.17B | +22.42% | 0.89% |
AVO | -0.98% | $836.83M | +19.94% | 0.00% |
MO | -1.00% | $98.96B | +28.98% | 6.98% |
FDP | 1.05% | $1.54B | +46.73% | 3.42% |
EGO | 1.13% | $4.08B | +34.35% | 0.00% |
EIG | 1.17% | $1.13B | +10.51% | 2.59% |
Yahoo
Nike upgraded, Sportradar initiated: Wall Street's top analyst calls
SeekingAlpha
Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight
Yahoo
Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced positive topline results from an interim analysis of its Phase 1 study for salanersen (BIIB115/ION306), which is an investigational antisense oligonucleotide/ASO for treating spinal muscular atrophy/SMA. Based on these encouraging findings, Biogen is engaging with global […]
Yahoo
New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA® (nusinersen) Final results from the landmark NURTURE study highlight the profound impact of early treatment with 12 mg SPINRAZA in clinically presymptomatic SMA with 92% of children achieving the ability to walk independently CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (N
Yahoo
CARLSBAD, Calif., June 25, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA® (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and e
Yahoo
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to re